Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan. 1 October 2024
AstronauTx, a biotech developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, has announced the appointment of Jane Rhodes as chief executive officer. 1 October 2024
Privately-held German pain specialist Grünenthal has appointed Jan Adams its new chief commercial officer (CCO) and a member of the corporate executive board. 30 September 2024
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara Magnone as its chief scientific officer. 26 September 2024
German privately-held biotech ARTCLINE Bio-Therapies today announced the appointment of Dirk Hessel as additional managing director of the company. 23 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
Current Boehringer Ingelheim chief medical officer Christopher Corsico is to move to British drugmaker GlaxoSmithKline at the end of the year. 20 September 2018
Canada’s Zymeworks, a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today named Anthony (Tony) Polverino, executive vice president of early development and chief scientific officer. 19 September 2018
Sanofi today announced that it will change the organizational structure of two of its Global Business Units (GBU) to provide greater focus on its operations in mature markets and across emerging markets. 13 September 2018
Based on its strong focus on the Asian market, French metabolic diseases biotech company Poxel has made another significant move to solidify its position, forming a fully-owned Japanese subsidiary, Poxel KK. 13 September 2018
A number of US hospitals are pressing ahead with plans to launch their own generics company, Civica Rx, with the appointment of Martin VanTrieste as chief executive. 11 September 2018
Boehringer Ingelheim today announced that Dr Christopher Corsico, senior vice president, corporate division Medicine and chief medical officer, will be leaving the German family-owned pharma major to pursue his career outside of the company effective December 31, 2018. 11 September 2018
Ironshore Pharmaceuticals, a wholly-owned subsidiary of Canada’s Highland Therapeutics, has appointed Scott Evangelista to the position of president and chief operating officer (COO). 7 September 2018
Rheos Medicines, a Boston, USA, biotech developing novel medicines that modulate metabolic pathways in immune cells to treat disease, has poached an experienced big pharma R&D leader from Roche to be its new chief executive. 6 September 2018
London-listed Arix Bioscience has announced a change to its executive team which will see current chief executive Joe Anderson moved to the role of chief investment officer. 4 September 2018
Switzerland-based Tillotts Pharma, part of the Japanese Zeria Group, has announced that Karima Boubekeur is joining the company to take on the newly-created role of global head of innovation. 3 September 2018
EMD Serono, the biopharmaceutical business of Merck KGaA in the USA and Canada, today announced that Rehan Verjee has been appointed president of EMD Serono and global head of innovative medicine franchises of Merck. 31 August 2018
Indianapolis, USA-based Eli Lilly has announced that Anne White is to become president of Lilly Oncology and senior vice president of Lilly, effective September 1, 2018. 31 August 2018
US pharma major Bristol-Myers Squibb yesterday announced that Christopher Boerner has been appointed executive vice president and chief commercial officer, effective immediately. 29 August 2018
Vertex Pharmaceuticals today announced that Ludovic Fenaux has been appointed senior vice president, international commercial operations with responsibility for commercial activities outside of the USA and Canada, which includes overseeing offices and operations across Europe, Australia and Latin America. 23 August 2018
Rare diseases specialist Swedish Orphan Biovitrum has appointed Anne Marie de Jonge Schuermans as head of its new Technical Operations organization, bringing together Sobi’s manufacturing operations/biological development and supply, quality, supply chain, procurement and environment and safety operations. 22 August 2018